Genelux Corp. (GNLX)
2.51
-0.03
(-1.18%)
USD |
NASDAQ |
Sep 09, 09:59
Genelux Debt to Equity Ratio : 0.1502 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.1502 |
| March 31, 2026 | 0.1089 |
| December 31, 2025 | 0.146 |
| September 30, 2025 | 0.0874 |
| June 30, 2025 | 0.0714 |
| March 31, 2025 | 0.0599 |
| December 31, 2024 | 0.0711 |
| September 30, 2024 | 0.0616 |
| June 30, 2024 | 0.0586 |
| March 31, 2024 | 0.1572 |
| December 31, 2023 | 0.1294 |
| Date | Value |
|---|---|
| September 30, 2023 | 0.0789 |
| June 30, 2023 | 0.0844 |
| March 31, 2023 | 1.343 |
| December 31, 2022 | -0.7365 |
| September 30, 2022 | -0.7862 |
| June 30, 2022 | -0.652 |
| March 31, 2022 | -0.6883 |
| December 31, 2021 | -0.7644 |
| September 30, 2021 | |
| June 30, 2021 | |
| March 31, 2021 | -1.029 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Arcutis Biotherapeutics, Inc. | 0.5174 |
| ACADIA Pharmaceuticals, Inc. | 0.0565 |
| Alnylam Pharmaceuticals, Inc. | 2.206 |
| Anika Therapeutics, Inc. | 0.1839 |
| Savara, Inc. | 0.2117 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 26.20M |
| Total Liabilities (Quarterly) | 10.09M |
| Shareholders Equity (Quarterly) | 16.11M |
| Current Ratio | 2.394 |
| Net Debt Paydown Yield | -0.09% |